GOG 107

Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

Date of Publication:

October 1, 2004

Pubmed Link:

Does the addition of cisplatin to doxorubicin improve response in women with advanced stage or recurrent endometrial cancer?

Control Arm(s):

doxorubicin 60mg/m2 q3 wks

Experimental Arm(s):

doxorubicin 60mg/m2 cisplatin 50mg/m2q3 wks

Primary End Point:

Response rate

Inclusion Criteria:

stage III, IV or recurrence endometrial cancerprior surgery and/or RT (prior hormonal or 1 biologic OK)measurable disease

Exclusion Criteria:

prior chemotherapy


doxorubicin (n=150) vs doxorubicin/cis (n=131):65% had prior RTgrade 3/4 leukopenia: 40% vs 62%grade 3/4 thrombocytopenia: 2% vs 14%grade 34/ anemia: 4% vs 22%grade 3/4 nausea/vomiting: 3% vs 13%RR: 25% vs 42% (SS)median PFS: 3.8 vs 5.7 mos (SS)median OS: 9.2 vs 9 mos (NS)


Addition of cisplatin to doxorubicin improves the response rate for women with advanced stage or recurrent endometrial cancer, yet adds toxicity. PFS, but not OS, are also improved.

Olga T Filippova